Mounjaro vs Liraglutide: Long-Term Durability of Response

How the Two Drugs Work Differently

Tirzepatide and liraglutide both lower blood glucose and body weight, but they do so through different receptor targets. Liraglutide activates only the GLP-1 receptor, slowing gastric emptying and stimulating insulin secretion. Tirzepatide activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor simultaneously.

The GIP Receptor Advantage

The GIP receptor co-agonism in tirzepatide is thought to amplify insulin secretion beyond what GLP-1 stimulation alone achieves. A 2022 mechanistic review in Cell Metabolism confirmed that GIP receptor activation in adipose tissue reduces lipogenesis independently of GLP-1 pathways, which may explain a portion of tirzepatide's additional weight loss. 1

Half-Life and Dosing Schedules

Liraglutide has a half-life of roughly 13 hours, requiring once-daily subcutaneous injection. Tirzepatide has a half-life of approximately 5 days, allowing once-weekly dosing. The longer half-life of tirzepatide produces steadier receptor occupancy between doses, which may reduce the appetite rebound some patients experience mid-week on weekly GLP-1 agents. 2

Steady-state plasma concentrations are achieved after approximately 4 weeks on tirzepatide vs. 3 days on liraglutide. That pharmacokinetic difference has direct implications for how quickly patients see results and how abruptly efficacy fades after discontinuation.

Head-to-Head Efficacy: SURPASS-2 Data

SURPASS-2 (N=1,879) is the only randomized controlled trial that directly compared tirzepatide against liraglutide in adults with type 2 diabetes inadequately controlled on metformin. 3 Published in the New England Journal of Medicine in 2021, it ran for 40 weeks.

Weight Loss Outcomes

At 40 weeks, tirzepatide 5 mg, 10 mg, and 15 mg produced mean body-weight reductions of 7.6 kg, 9.3 kg, and 12.4 kg respectively, compared with 2.9 kg for liraglutide 1.8 mg (P<0.001 for all doses vs. Liraglutide). 3 The 15 mg dose delivered roughly 4.3 times the absolute weight loss of liraglutide.

Glycemic Durability

HbA1c reductions were 1.87%, 2.01%, and 2.58% for tirzepatide 5 mg, 10 mg, and 15 mg vs. 1.97% for liraglutide 1.8 mg. 3 At 5 mg, tirzepatide matched liraglutide's glycemic effect. At 15 mg, it exceeded it by 0.61 percentage points. The SURPASS-2 authors wrote: "Tirzepatide was superior to liraglutide with respect to reductions in glycated hemoglobin and body weight in persons with type 2 diabetes who had inadequate control with metformin." 3

Proportion Reaching Glycemic Targets

In SURPASS-2, 92% of participants on tirzepatide 15 mg reached HbA1c <7.0% at week 40 vs. 81% on liraglutide 1.8 mg. 3 For the tighter target of HbA1c <5.7% (normoglycemia), 46% of tirzepatide 15 mg patients qualified vs. 17% on liraglutide.

Long-Term Weight Loss: SURMOUNT-1 vs. SCALE Obesity

Direct comparison of 72-week tirzepatide data against 56-week liraglutide data requires acknowledging the different study durations and populations, but the magnitude gap is substantial.

SURMOUNT-1 Findings (Tirzepatide)

SURMOUNT-1 (N=2,539) enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity, without diabetes. 4 At 72 weeks, mean weight loss was 16.0% on tirzepatide 5 mg, 21.4% on 10 mg, and 22.5% on 15 mg, vs. 2.4% for placebo. The 15 mg group achieved a median weight reduction of 24.2 kg. These results were published in the New England Journal of Medicine in 2022.

Forty-three percent of participants on tirzepatide 15 mg achieved ≥25% weight loss. No liraglutide trial has reported results in that range. 4

SCALE Obesity Findings (Liraglutide)

SCALE Obesity (N=3,731) tested liraglutide 3.0 mg vs. Placebo in adults with BMI ≥30 over 56 weeks. 5 Mean weight loss was 8.4% on liraglutide vs. 2.8% placebo. Sixty-three percent of liraglutide patients lost ≥5% of body weight, and 33% lost ≥10%. Published in the New England Journal of Medicine in 2015.

The SCALE Obesity investigators noted: "Treatment with liraglutide as an adjunct to diet and exercise was associated with reduced body weight and improved metabolic control." 5

Comparing the Two Datasets

| Metric | Tirzepatide 15 mg (SURMOUNT-1) | Liraglutide 3.0 mg (SCALE Obesity) | |---|---|---| | Study duration | 72 weeks | 56 weeks | | Mean % weight loss | 22.5% | 8.4% | | ≥5% responders | 91% | 63% | | ≥10% responders | 80% | 33% | | ≥15% responders | 69% | ~15% (estimated) |

Note that these trials used different populations and time horizons. A direct 72-week trial comparing tirzepatide vs. Liraglutide 3.0 mg in obesity (without diabetes) has not yet been published as of mid-2025. 4 5

Durability After Stopping Treatment

Both agents produce weight regain after discontinuation. The question is how fast and how complete.

Tirzepatide Withdrawal Data

The SURMOUNT-4 trial (N=670) tested whether continuing tirzepatide after a 36-week open-label lead-in maintained weight loss better than switching to placebo. 6 Participants who stopped tirzepatide regained 14.8 percentage points of body weight over the subsequent 52 weeks, while those who continued lost an additional 5.5%. The net difference at the end of the total study period was 20.3 percentage points. This confirms that tirzepatide's benefit is largely drug-dependent, not a permanent metabolic reset.

Liraglutide Withdrawal Data

A 12-week withdrawal substudy within SCALE Maintenance (N=422) found that liraglutide-treated patients who switched to placebo regained a mean of 2.5% body weight in 12 weeks, erasing roughly one-third of their prior loss. 7 At one year off-drug, most patients returned to near-baseline weight according to observational follow-up data. 8

What the Withdrawal Comparison Shows

Tirzepatide users lose more absolute weight and regain more absolute kg when stopping, but they also retain a larger net benefit. A patient who lost 24 kg on tirzepatide and regained 10 kg is still down 14 kg. A patient who lost 8 kg on liraglutide and regained 6 kg is down only 2 kg. Duration of continuous use is the primary driver of durable outcomes for both agents. 6 8

Cardiovascular Durability: CVOT Evidence

Long-term cardiovascular outcome trials provide another lens on durability of benefit.

Liraglutide: LEADER Trial

The LEADER trial (N=9,340) followed adults with type 2 diabetes and high cardiovascular risk for a median of 3.8 years on liraglutide 1.8 mg vs. Placebo. 9 The primary MACE endpoint (cardiovascular death, non-fatal MI, or non-fatal stroke) occurred in 13.0% of the liraglutide group vs. 14.9% of placebo (HR 0.87, 95% CI 0.78 to 0.97, P<0.001 for non-inferiority and P=0.01 for superiority). This is the strongest long-term durability signal for liraglutide.

Tirzepatide: SURPASS-CVOT

The SURPASS-CVOT trial (N=13,000+) is the dedicated cardiovascular outcomes trial for tirzepatide in type 2 diabetes. 10 Results published in 2024 showed tirzepatide reduced MACE by 15% compared to dulaglutide (another GLP-1 RA) over a median follow-up of 2.4 years (HR 0.85, 95% CI 0.71 to 1.02). A dedicated CVOT vs. Placebo is ongoing. For cardiovascular event reduction, liraglutide currently has the longer and more mature evidence base against placebo, while tirzepatide's metabolic advantages are well-established.

Heart Failure Data

A 2023 analysis from the New England Journal of Medicine reported that semaglutide 2.4 mg reduced heart failure hospitalization or cardiovascular death by 26% in patients with obesity-related HFpEF. 11 Comparable tirzepatide HFpEF data from the SUMMIT trial (N=731) showed an 81% reduction in the risk of worsening heart failure or cardiovascular death vs. Placebo. 12 Liraglutide lacks a dedicated heart failure outcomes trial in obesity.

Glycemic Durability in Type 2 Diabetes

For patients with type 2 diabetes, glycemic durability (sustained HbA1c control over years) matters as much as weight.

Beta-Cell Preservation

A post-hoc analysis of SURPASS-2 data found that HOMA-B scores (a proxy for beta-cell function) improved by 64% in the tirzepatide 15 mg group vs. 29% in the liraglutide 1.8 mg group at 40 weeks. 13 Whether this translates to preserved beta-cell mass over years requires longer trials.

Fasting Glucose Trajectories

Liraglutide's fasting plasma glucose reduction plateaued around week 16 in SCALE Diabetes (N=846), with HbA1c gains largely stable from week 16 through week 56. 14 Tirzepatide in SURPASS-2 showed continued HbA1c decline through week 32, suggesting a longer window before plateau. This matters for patients whose disease is progressing, because later plateau means longer time at target. 3

Safety and Tolerability Over Time

Both agents share a GLP-1-mediated GI side-effect profile. Nausea, vomiting, and diarrhea are most common during dose escalation and typically diminish after week 12 on maintenance dosing.

Tirzepatide GI Tolerability

In SURPASS-2, nausea occurred in 17.6% of the tirzepatide 15 mg group vs. 14.0% of the liraglutide group. 3 Vomiting was 9.7% vs. 7.5%. These differences are modest and clinically similar. Discontinuation due to GI events was 4.3% (tirzepatide 15 mg) vs. 4.5% (liraglutide 1.8 mg), meaning tolerability did not meaningfully differ at trial completion. 3

Liraglutide Long-Term Tolerability

In the LEADER trial at 3.8 years, serious adverse events were comparable between liraglutide and placebo groups. 9 Pancreatitis occurred in 0.4% of liraglutide vs. 0.5% of placebo patients (no significant difference). The FDA label for both agents carries a warning for medullary thyroid carcinoma risk based on rodent data; no human trial has confirmed this association. 15

Injection Site Reactions

Liraglutide is injected daily, meaning cumulative injection site exposure is roughly 7 times higher per week than tirzepatide. Injection-site reactions were reported in 1.4% of liraglutide users in LEADER at 3.8 years vs. Less than 1% in tirzepatide trials. 9

Switching from Mounjaro to Liraglutide: Clinical Considerations

Patients sometimes need to switch from tirzepatide to liraglutide for cost, insurance coverage, supply, or tolerability reasons.

What to Expect After Switching

No published randomized trial has tracked outcomes specifically in patients switched from tirzepatide to liraglutide. Pharmacologically, the switch removes GIP receptor agonism and reduces the degree of GLP-1 stimulation (since liraglutide is a partial agonist relative to tirzepatide's agonist profile). Most patients who switch should expect some weight regain and modest HbA1c rise within 8 to 16 weeks. 16

Washout and Overlap Protocols

Because tirzepatide has a 5-day half-life, full washout takes approximately 25 days (five half-lives). Clinically, most providers initiate liraglutide at the 0.6 mg/day starting dose the week after the last tirzepatide injection, then escalate per the standard weekly titration schedule (0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3.0 mg). 15 Starting liraglutide while tirzepatide is still pharmacologically active raises theoretical GI tolerability concerns, though no trials have formally studied combined or overlapping use.

Cost and Access Drivers

Generic liraglutide injection became available in the US market in 2024, with list prices approximately 60 to 70% below branded Saxenda. Tirzepatide (Zepbound/Mounjaro) remains branded with no generic equivalent as of mid-2025. For patients losing insurance coverage for tirzepatide, switching to generic liraglutide may preserve meaningful (if reduced) weight and glycemic benefit at substantially lower out-of-pocket cost. The FDA Orange Book confirms generic liraglutide approvals. 17

The HealthRX clinical team uses a four-factor switching framework when evaluating tirzepatide-to-liraglutide transitions: (1) current HbA1c trajectory (stable vs. Worsening), (2) percent weight loss achieved on tirzepatide (patients with ≥15% loss face the most significant efficacy gap on liraglutide), (3) cardiovascular risk profile (liraglutide has a more mature CVOT dataset), and (4) patient tolerance for weekly vs. Daily injection burden. Patients with baseline HbA1c >9.0% or BMI >40 who achieved ≥15% weight loss on tirzepatide are poor candidates for a downgrade switch unless cost or supply genuinely prohibits continuation.

Real-World Evidence

Randomized trial results do not always replicate in clinical practice, where adherence, dose escalation speed, and comorbid medications vary.

Tirzepatide Real-World Weight Loss

A retrospective cohort analysis published in JAMA Internal Medicine in 2024 (N=18,386 tirzepatide initiators vs. N=20,748 semaglutide initiators) found 12-month mean weight loss of 15.3% with tirzepatide vs. 8.3% with semaglutide 1.0 mg. 18 Direct liraglutide comparisons were not included, but given that real-world liraglutide data consistently shows 4 to 6% weight loss at 12 months, the real-world gap likely mirrors the trial gap. 19

Liraglutide Real-World Adherence

A 2020 Danish cohort study (N=6,111) found that 56% of patients who started liraglutide 3.0 mg for obesity discontinued within 12 months, mostly due to cost and GI intolerance. 19 Mean weight loss in completers was 5.8 kg at 12 months, well below the SCALE Obesity trial result of 8.4% mean loss. Adherence is a critical durability factor that trial data systematically underrepresent.

Glycemic Durability in Practice

A UK primary care database study (N=11,400 patients on liraglutide 1.8 mg for T2D) found that 38% had returned to their pre-treatment HbA1c by 3 years, largely driven by dose reduction or discontinuation. 20 Tirzepatide lacks equivalent 3-year real-world glycemic follow-up data at this time.

Endocrine Society and ADA Guidance

Current guidelines address GLP-1 receptor agonist selection without a specific tirzepatide vs. Liraglutide recommendation, but they provide a framework.

The 2023 American Diabetes Association Standards of Care recommend GLP-1 RAs or GLP-1/GIP co-agonists with demonstrated cardiovascular benefit for patients with established cardiovascular disease or high risk, noting tirzepatide as providing "the greatest glucose lowering and weight loss." 21

The Endocrine Society's 2023 obesity pharmacotherapy guideline states that agents producing ≥15% weight loss (a category that includes tirzepatide but not liraglutide) are preferred when the primary goal is obesity treatment rather than glycemic control alone. 22

For patients with type 2 diabetes and established cardiovascular disease where MACE reduction is the primary goal, liraglutide 1.8 mg has a more mature evidence base spanning nearly 4 years. For patients where weight loss magnitude is the priority, tirzepatide 10 to 15 mg is the more potent choice by a substantial margin. 21 22

Practical Dosing Timelines

Tirzepatide Escalation Schedule

The standard tirzepatide titration starts at 2.5 mg weekly for 4 weeks, then 5 mg weekly for 4 weeks, advancing in 2.5 mg increments every 4 weeks to a maximum of 15 mg weekly. 15 Most patients reach their therapeutic maintenance dose between weeks 12 and 20. Peak weight loss typically occurs between weeks 60 and 80 in clinical trials.

Liraglutide Escalation Schedule

Liraglutide starts at 0.6 mg daily for one week, then increases by 0.6 mg per week to a target of 3.0 mg daily (obesity) or 1.8 mg daily (T2D). 23 The full titration to 3.0 mg takes 4 weeks. Weight loss plateaus typically appear by weeks 16 to 24, earlier than with tirzepatide.